17.09.2024 – 14:05PNO Innovation GmbHLaunch of canSERV Call for Service Provision – "Training the Next Generation of Cancer Researchers"Challenge CallOne documentmore
09.09.2024 – 09:06Sysmex Europe SE2Fundació Puigvert validates a new tool capable of selecting the most suitable antibiotic for uncomplicated urinary tract infections within 45 minutes.Visit our website!One documentmore
04.09.2024 – 15:13Fördergesellschaft IZB mbH2Record financing rounds at the Munich biotech hubFind out more about the 40+ biotech start-ups at the IZBOne documentmore
03.09.2024 – 11:10Bosch Healthcare Solutions GmbHNear-patient PCR rapid test for whooping cough for Vivalytic by Bosch now available / World's first fully automated PCR test for detection of B. pertussis, B. parapertussis, B. holmesiimore
29.08.2024 – 14:03PNO Innovation GmbHcanSERV relaunches Open Call for Service ProvisionOpen CallOne documentmore
28.08.2024 – 07:34STADA Arzneimittel AGPress release: STADA continues strong growth journey in the first half of 2024One documentmore
18.07.2024 – 11:05Bosch Healthcare Solutions GmbHPCR rapid test for 3 important gastroenteritis pathogens for Vivalytic by Bosch now available / World’s first fully automated PCR test for detection of C. difficile, norovirus, and rotavirus at the sampling pointmore
02.07.2024 – 14:00PNO Innovation GmbHcanSERV to Accelerate Your Cancer Research - 2 Calls for Service Provision OpencanSERV Challenge Calls2 Documentsmore
13.06.2024 – 10:05Sysmex Europe SE4Sysmex’s PA-100 AST System Wins One of the UK’s Biggest Science PrizesVisit our website!One documentmore
05.06.2024 – 17:10Helmholtz MunichNew Study: Father's Diet Before Conception Influences Children's HealthNewsroommore
28.05.2024 – 14:05PNO Innovation GmbHcanSERV invites applications for "Revolutionising Cancer Patient Care"canSERV Challenge CallOne documentmore
28.05.2024 – 14:00PNO Innovation GmbH3canSERV invites applications for "Revolutionising Cancer Patient Care"canSERV CallOne documentmore
21.05.2024 – 08:13Helmholtz MunichNew Study: Night-time heat significantly increases the risk of strokeNewsroommore
14.05.2024 – 09:01PNO Innovation GmbHLAST CHANCE: canSERV Second Open Call for Cancer Research Service ProvisioncanSERV Open Call One documentmore
23.04.2024 – 14:02PNO Innovation GmbH3canSERV Initiative: EU Consortium Launches Groundbreaking Call to Accelerate Cancer ResearchcanSERV Challenge CallOne documentmore
10.04.2024 – 11:00Dr. Reddy's Laboratories SADr. Reddy's subsidiary betapharm, and Theranica launch Nerivio® in Germany to provide patients with drug-free migraine treatmentmore
02.04.2024 – 11:10Helmholtz MunichScientists Reveal Adipocyte's Metabolic Role and Identify Treatment Targetsmore
14.03.2024 – 07:31STADA Arzneimittel AGPress release: STADA continues with double-digit sales and profit growth in 2023One documentmore
13.03.2024 – 16:21FDX Fluid Dynamix GmbH4FDX Fluid Dynamix and Fraunhofer IPK to Collaborate with Lonza on Novel Nanoparticle Formulation Technology Platform FDmiXmore
28.02.2024 – 15:00RHEACELL GmbH und Co. KGResearch Success in Rare Disease / RHEACELL receives positive signal for accelerated stem cell development program in rare ‚Butterfly Disease‘more
28.02.2024 – 11:07Helmholtz MunichRising Focus on 'Inceptor' as a Type 2 Diabetes Therapeutic Targetmore
23.02.2024 – 10:28Leipzig Tourismus und Marketing GmbH5Pioneering Heart Surgery and Medical Congresses in LeipzigOne documentmore
22.02.2024 – 13:23Helmholtz MunichTherapeutic Vaccine for Chronic Hepatitis B Enters Clinical TrialMore information on the therapeutic vaccine TherVacBmore
19.02.2024 – 17:05Helmholtz MunichWhat Our Genetic Information Tells Us About Type 2 Diabetes Risk and ComplicationsLearn more about research at Helmholtz Munichmore
16.11.2023 – 10:27Fruit Vegetables EuropeTen benefits of a daily intake of citrus fruits during winter seasonmore
30.08.2023 – 12:28STADA Arzneimittel AG2Press release : People with Parkinson’s experience variations in effects of oral medicines, but lack advice, international survey revealsOne documentmore
27.06.2023 – 11:23RHEACELL GmbH und Co. KGRHEACELL announces “First Patient In”: EB-Haus in Salzburg, Austria starts pivotal study for stem cell therapy for severe forms of Epidermolysis bullosa that is longed for by those affectedmore
23.03.2023 – 12:04hubergroup Deutschland GmbH5Press Release - hubergroup India expands its support for rural healthcareMore about hubergroupOne documentmore